Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 15, 2024 - Issue
Submit an article Journal homepage
116
Views
0
CrossRef citations to date
0
Altmetric
EXPERT OPINION

Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

Sai-Hong Ignatius Ou1 University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1764-4975
ORCID Icon,
Xiuning Le2 University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Misako Nagasaka1 University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USAORCID Iconhttps://orcid.org/0000-0001-5308-615X
ORCID Icon,
Thanyanan Reungwetwattana3 Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, ThailandORCID Iconhttps://orcid.org/0000-0002-3147-7640
ORCID Icon,
Myung-Ju Ahn4 Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Darren WT Lim5 Duke-NUS School of medicine, National Cancer Center Singapore, Republic of Singapore
,
Edgardo S Santos6 Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, 33431, USAORCID Iconhttps://orcid.org/0000-0003-0776-4903
ORCID Icon,
Elaine Shum7 NYU Langone Perlmutter Cancer Center, NY, NY, USA
,
Sally CM Lau7 NYU Langone Perlmutter Cancer Center, NY, NY, USA
,
Jii Bum Lee8 Yonsei Cancer Center Yonsei University, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-5608-3157
ORCID Icon,
Antonio Calles9 Department of Medicine, Division of Medical Oncology, Early Drug Development and Phase I Unit, Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain
,
Fengying Wu10 Shanghai Chest hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China
,
Gilberto Lopes11 Department of Medicine, Division of Medical Oncology, Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, FL, 33136, USA
,
Virote Sriuranpong12 Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, ThailandORCID Iconhttps://orcid.org/0000-0002-7847-894X
ORCID Icon,
Junko Tanizaki13 Department of Medicine, Kindai University School of Medicine, Osaka, Japan
,
Hidehito Horinouchi14 Department of Thoracic Oncology, National Cancer Center Hospital Tokyo, Tokyo, Japan
,
Marina C Garassino15 Department of Medicine, Division of Medical Oncology-Hematology, University of Chicago Medicine, Chicago, IL, USA
,
Sanjay Popat16 Royal Marsden Hospital, London, Imperial College, London, UK
,
Benjamin Besse17 Gustave Roussy Cancer Campus, Villejuif, France; Paris-Saclay University, Orsay, France
,
Rafael Rosell18 Department of Hematology-Oncology, National University Cancer Institute, National University Hospital Singapore, Republic of SingaporeORCID Iconhttps://orcid.org/0000-0003-0817-3400
ORCID Icon &
Ross A Soo19 IOR, Quirón-Dexeus University Institute; ICO, Catalan Institute of Oncology; IGTP, Germans Trias i Pujol Research Institute, Barcelona, Spain
 show all
Pages 87-114 | Received 15 Mar 2024, Accepted 27 May 2024, Published online: 21 Jun 2024

References

  • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. PMID: 15118073. doi:10.1056/NEJMoa040938
  • Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. PMID: 15118125. doi:10.1126/science.1099314
  • Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from ”never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306–13311. PMID: 15329413. doi:10.1073/pnas.0405220101
  • Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64(24):8919–8923. doi:10.1158/0008-5472.CAN-04-2818
  • Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004;10(24):8195–8203. doi:10.1158/1078-0432.CCR-04-1245
  • Mok TS, Y-L W, Thongprasert S. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. doi:10.1056/NEJMoa0810699
  • Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181. doi:10.1038/nrc2088
  • Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21(12):2237–2246. doi:10.1200/JCO.2003.10.038
  • Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–2158. doi:10.1001/jama.290.16.2149
  • Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3238–3247. doi:10.1200/JCO.2004.11.057
  • Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566. doi:10.1038/nature05945
  • Rikova R, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:190–203. doi:10.1016/j.cell.2007.11.025
  • Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436–445. doi:10.1101/gr.133645.111
  • Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18:375–377. doi:10.1038/nm.2644
  • Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378–381. doi:10.1038/nm.2658
  • Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382–384. doi:10.1038/nm.2673
  • Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–1128. doi:10.1200/JCO.2011.36.8456
  • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–1537. doi:10.1016/S0140-6736(05)67625-8
  • Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: post-hoc analyses from the Phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 2017;104:119–125. doi:10.1016/j.lungcan.2016.11.022
  • Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R. Webster A, et al First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110:55–62. doi:10.1038/bjc.2013.721
  • Kazandjian D, Blumenthal GM, Yuan W, et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res. 2016;22(6):1307–1312. doi:10.1158/1078-0432.CCR-15-2266
  • Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391–3402. doi:10.1200/JCO.21.00662
  • Zhou C, Ramalingam S, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7(12):e214761. doi:10.1001/jamaoncol.2021.4761
  • Jänne P, Wang B, Cho BC, et al. EXCLAIM-2: phase 3 trial of first-line mobocertinib versus platinum-based chemotherapy in patients with EGFR exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC. Ann Oncol. 2023;34(4):S1663–S1664. doi:10.1016/j.annonc.2023.10.586
  • Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023;389(22):2039–2051. doi:10.1056/NEJMoa2306441
  • Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2023;S2213-2600(23):1.
  • Dhillon S. Sunvozertinib: first Approval. Drugs. 2023;83(17):1629–1634. doi:10.1007/s40265-023-01959-5
  • Sa H, Shi Y, Ding C, Ma K. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. J Cancer Res Clin Oncol. 2023;149(10):7729–7742. doi:10.1007/s00432-023-04726-x
  • Piotrowska Z, Tan DS, Smit EF, et al. Safety, tolerability, and antitumor activity of zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions. J Clin Oncol. 2023;41(26):4218–4225. doi:10.1200/JCO.23.00152
  • Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa1913662
  • Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
  • Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935–1948. doi:10.1056/NEJMoa2306434
  • Cho BC, Felip E, Spira AI, et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial. ESMO Congress 2023, LBA14; 2023.
  • Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–1723. doi:10.1056/NEJMoa2027071
  • Koch AL, Vellanki PJ, Drezner N, et al. FDA approval summary: osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative project orbis review. Clin Cancer Res. 2021;27(24):6638–6643. doi:10.1158/1078-0432.CCR-21-1034
  • Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389(2):137–147. doi:10.1056/NEJMoa2304594
  • Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage ib-iiia non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41(10):1830–1840. doi:10.1200/JCO.22.02186
  • Soo RA, de Marinis F, Han JY, et al. TARGET: a Phase II, Open-Label, Single-Arm Study of 5-year adjuvant osimertinib in completely resected EGFR-mutated stage II to IIIB NSCLC post complete surgical resection. Clin Lung Cancer. 2024;25(1):80–84. doi:10.1016/j.cllc.2023.09.005
  • Hill W, Lim EL, Weedan CE, et al. Lung adenocarcinoma promotion by air pollutants. Nature. 2023;616(7955):159–167. doi:10.1038/s41586-023-05874-3
  • Triphuridet N, Zhang SS, Nagasaka M. Low-dose computed tomography (LDCT) lung cancer screening in Asian female never-smokers is as efficacious in detecting lung cancer as in Asian male ever-smokers: a systematic review and meta-analysis. J Thorac Oncol. 2023;18(6):698–717. doi:10.1016/j.jtho.2023.01.094
  • Lee LN, Lee ATM, Nagasaka M, Ou SI. Chemotherapy and Osimertinib combination should be the first-line treatment for all advanced EGFR+ NSCLC. J Thorac Oncol. 2024;2024:1.
  • Lim SM, Lee JB, Cho BC. Chemotherapy and osimertinib combination should Not be the first-line treatment for all advanced EGFR+++ NSCLC. J Thorac Oncol. 2024;19:376–379. doi:10.1016/j.jtho.2023.12.007
  • Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther. 2020;19:2044–2056. doi:10.1158/1535-7163.MCT-20-0071
  • Lu S, Cho BC, Lee JS, et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA subgroup analysis. Ann Oncol. 2023;34(SUPPLEMENT 4):S1661. doi:10.1016/j.annonc.2023.10.582
  • Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–792. doi:10.1056/NEJMoa044238
  • Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-posimertinibtive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa1612674
  • Sequist LV, Waltman BA, Dias-Santagata D. Dias-Santagata D, et al Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. doi:10.1126/scitranslmed.3002003
  • Rath B, Plangger A, Hamilton G. Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer. Cancer Drug Resist. 2020;3(2):171–178. doi:10.20517/cdr.2019.85
  • Qin K, Hong L, Zhang J, Le X. MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: clinical Challenges and Opportunities. Cancers (Basel). 2023;15(3):612. doi:10.3390/cancers15030612
  • Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373–386. doi:10.1016/S1470-2045(19)30785-5
  • Yang JC, Sequist LV, Geater SL, et al. Clinical activity of Afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838. doi:10.1016/S1470-2045(15)00026-1
  • Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr. Accessed May 27, 2024.
  • Miura S, Tanaka H, Misumi T, et al. LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: a phase III study (ACHILLES/TORG1834). Ann Oncol. 2023;34(2):S1310–1311. doi:10.1016/j.annonc.2023.10.067
  • Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536–1544. doi:10.1016/j.annonc.2020.08.2100
  • Cho BC, Han JY, Kim SW, et al. A phase 1/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2022;17:558–567. doi:10.1016/j.jtho.2021.11.025
  • Lu S, Wang Q, Zhang G, et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790Mþ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial. J Thorac Oncol. 2022;17:411–422. doi:10.1016/j.jtho.2021.10.024
  • Shi Y, Hu X, Zhang S, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021;9:829–839. doi:10.1016/S2213-2600(20)30455-0
  • Lu S, Zhang Y, Zhang G, et al. Efficacy and Safety of Befotertinib (D-0316) in Patients with EGFR T790M-Mutated NSCLC that had progressed after prior EGFR tyrosine kinase inhibitor therapy: a phase 2, multicenter, single-arm, open-label study. J Thorac Oncol. 2022;17(10):1192–1204. doi:10.1016/j.jtho.2022.06.002
  • Shi Y et al. (2022). Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study. Journal of Thoracic Oncology, 17(11), 1306–1317. 10.1016/j.jtho.2022.08.015
  • Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2023;23:S0923–7534.
  • Chen MF, Piotrowska Z, Yu HA. POSing the question: MARIPOSA-2, do the ends justify the means? Ann Oncol. 2024;35(1):4–6. doi:10.1016/j.annonc.2023.11.005
  • Lee ATM, Ou SI. MARIPOSA-2: is treatment worse than the disease? Med. 2024. doi:10.1016/j.medj.2024.05.005
  • Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(9):1167–1179. doi:10.1016/S1470-2045(22)00382-5
  • Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624–636. doi:10.1016/S2213-2600(23)00135-2
  • Zhou C, Dong X, Chen G, et al. IMpower151: phase III study of atezolizumab + bevacizumab + chemotherapy in first-line metastatic nonsquamous NSCLC. Presented at: 2023 IASLC World Conference on Lung Cancer. Singapore, Republic of Singapore; 2023.
  • Park S, Kim TM, Han JY, et al. A phase 3, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024;42(11):1241–1251. doi:10.1200/JCO.23.01891
  • Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-0
  • Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732–737. doi:10.1038/s41586-021-03898-1
  • Yenerall P, Kittler R, Minna J. Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy. Cancer Cell. 2021;39(11):1455–1457. doi:10.1016/j.ccell.2021.10.012
  • Gower A, Garon EB. Targeting more precisely: improving sensitivity to EGFR inhibitors in NSCLC. Med. 2021;2(11):1201–1202. doi:10.1016/j.medj.2021.10.005
  • Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216):216ra177. doi:10.1126/scitranslmed.3007205
  • Vasconcelos PENS, Gergis C, Viray H, et al. EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors. JTO Clin Res Rep. 2020;1(3):100051. doi:10.1016/j.jtocrr.2020.100051
  • Lisberg A, Cummings A, Goldman JW, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol. 2018;13(8):1138–1145. doi:10.1016/j.jtho.2018.03.035
  • Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
  • Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-7
  • Yang JCH, Lee DH, Park K, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study. J Clin Oncol. 2023;41:LBA9000–LBA9000. doi:10.1200/JCO.2023.41.17_suppl.LBA9000
  • Mok T, Nakagawa K, Park K, et al. Nivolumab + chemotherapy versus chemotherapy in patients with EGFR-mutated metastatic non-small cell lung cancer with disease progression after EGFR tyrosimertinibne kinase inhibitors in CheckMate 722. Ann Oncol. 2022;33:S1561–S1562. doi:10.1016/j.annonc.2022.10.350
  • Zhu VW, Klempner SJ, Ou SI. Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer. Trends Cancer. 2019;5(11):677–692. doi:10.1016/j.trecan.2019.09.008
  • Kobayashi Y, Oxnard G, Cohen EY, et al. Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nat Commun. 2022;13(1):5614. doi:10.1038/s41467-022-33210-2
  • Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–562. doi:10.1038/nm.3854
  • Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–2294. doi:10.1056/NEJMoa1400029
  • Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–737. doi:10.1038/s41416-019-0573-8
  • Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18(4):521–528. doi:10.1038/nm.2713
  • Cardona AF, Rojas L, Wills B, et al. BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget. 2016;7(42):68933–68942. doi:10.18632/oncotarget.12112
  • Lv F, Sun L, Yang Q, et al. Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: a Meta-Analysis. Biomed Res Int. 2021;2021:3621828. doi:10.1155/2021/3621828
  • Zhang L, Jiang T, Li X, et al. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. Cancer. 2017;123(15):2927–2935. doi:10.1002/cncr.30677
  • Li W, Fei K, Guo L, et al. CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in NSCLC Independent of TP53 mutations. J Thorac Oncol. 2023;2023:S1556-0864(23)02414–0.
  • Cardona AF, Ordóñez-Reyes C, Ruiz-Patiño A, et al. EGFR inhibitors plus bevacizumab are superior to EGFR inhibitors alone as first-line setting in advanced NSCLC With EGFR mutations and bim deletion polymorphisms (BIM-CLICaP). JCO Precis Oncol. 2021;5:839–848. doi:10.1200/PO.20.00404
  • Liu S, He Y, Jiang T, et al. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. Lung Cancer. 2018;120:82–87. doi:10.1016/j.lungcan.2018.04.004
  • Ahn MJ, Cho BC, Ou X, et al. Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial. J Thorac Oncol. 2022;17(5):718–723. doi:10.1016/j.jtho.2022.01.012
  • Yang JCH, Shepherd FA, Kim DW, et al. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-Posimertinibtive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019;14(5):933–939. doi:10.1016/j.jtho.2019.02.001
  • Lu S, Dong X, Jian H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or l858r mutations. J Clin Oncol. 2022;40(27):3162–3171. doi:10.1200/JCO.21.02641
  • Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022;10(11):1019–1028. doi:10.1016/S2213-2600(22)00168-0
  • Cho BC, Ahn MJ, Kang JH, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301. J Clin Oncol. 2023;41(26):4208–4217. doi:10.1200/JCO.23.00515
  • Lu S, Zhou J, Jian H, et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir Med. 2023;11(10):905–915. doi:10.1016/S2213-2600(23)00183-2
  • Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:3290–3297. doi:10.1200/JCO.2018.78.3118
  • Jänne PA, Blanchard D, Kobayashi K, et al. CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor–mutated advanced non–small-cell lung cancer. J Clin Oncol. 2023;2024:1.
  • Gray JE, Ahn MJ, Oxnard GR, et al. Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA. Clin Cancer Res. 2023;29(17):3340–3351. doi:10.1158/1078-0432.CCR-22-3146
  • Papadimitrakopoulou VA, Han JY, Ahn MJ, et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2020;126(2):373–380. doi:10.1002/cncr.32503
  • Gray JE, Okamoto I, Sriuranpong V, et al. Tissue and Plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator egfr tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;25(22):6644–6652. doi:10.1158/1078-0432.CCR-19-1126
  • Vaclova T, Grazini U, Ward L, et al. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nat Commun. 2021;12(1):1780. doi:10.1038/s41467-021-22057-8
  • Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. doi:10.1056/NEJMoa1411817
  • Yver A. Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development. Ann Oncol. 2016;27(6):1165–1170. doi:10.1093/annonc/mdw129
  • Fourie Zirkelbach J, Shah M, Vallejo J, et al. Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. J Clin Oncol. 2022;40(30):3489–3500. doi:10.1200/JCO.22.00371
  • Brown H, Vansteenkiste J, Nakagawa K, et al. Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. J Thorac Oncol. 2020;15(1):138–143. doi:10.1016/j.jtho.2019.09.009
  • Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a Phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41(35):5363–5375. doi:10.1200/JCO.23.01476
  • Mok T, Jänne PA, Nishio M, et al. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future Oncol. 2023;20:969–980. doi:10.2217/fon-2023-0602
  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–132. doi:10.1056/NEJMoa050753
  • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi:10.1016/S1470-2045(11)70393-X
  • Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30(5):839–844. doi:10.1093/annonc/mdz077
  • Jänne PA, Baik C, Su WC, et al. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2022;12(1):74–89. doi:10.1158/2159-8290.CD-21-0715
  • Lu, S, Kato, T, Dong, X Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. Available from: https://www.nejm.org/doi/abs/10.1056/NEJMoa2402614. Accessed June 2, 2024 2024.
  • Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937
  • Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi:10.1056/NEJMoa1809697
  • Han B, Zhou C, Zheng W, et al. A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions. Presented at: International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer. Singapore; 2023.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.